Clinical Trial

Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 27, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
This phase II trial studies how well gemcitabine, cisplatin and durvalumab/Pembrolizumab and surufatinib work in treating participants with advanced Biliary Tract Cancer. The international multicenter phase III clinical study TOPAZ-1 has confirmed that durvalumab combined with gemcitabine and cisplatin can bring survival benefits to advanced BTC. Whether if adding surufatinib to a standard of care can bring addition benefit needs to be explored.
Trial Details
NCT Number NCT06708858
Lead Sponsor Dai, Guanghai
Conditions Advanced Biliary Tract Cancer
Enrollment 35 participants
Start Date 2024-08-15
Primary Completion 2025-12 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2024-11-27